Clinical trials located in

Sankt Augustin

Sankt Augustin city is located in Germany. Currently, 9 clinical trials are being conducted in this city.

Sankt Augustin, located in North Rhine-Westphalia, Germany, is a city with a rich history and modern appeal. Named after the patron saint of the Divine Word Missionaries, it was established in 1969 through the amalgamation of several older communities. Home to a significant campus of the Hochschule Bonn-Rhein-Sieg (University of Applied Sciences), the city is a hub for education and innovation. Notably, Sankt Augustin hosts the headquarters of the German Aerospace Center (DLR), emphasizing its role in scientific research and development. Its blend of historical roots and contemporary significance makes it a unique part of the German landscape.

  • CT-EU-00118080

    Evaluating upadacitinib and tocilizumab in pediatric and adolescent patients with active systemic juvenile idiopathic arthritis

    This clinical trial is designed for pediatric and adolescent participants aged 1 to less than 18 years with systemic Juvenile Idiopathic Arthritis (sJIA). The study aims to evaluate the safety and effectiveness of upadacitinib, an oral medication, and includes a reference arm for tocilizumab, which can be administered subcutaneously or intravenously.

    Participants will be assigned to one of two cohorts. Cohort 1 (group) will receive either upadacitinib or tocilizumab, while Cohort 2 will receive upadacitinib only. The treatment period will last 52 weeks, followed by a 30-day follow-up. The study will monitor changes in disease activity and adverse events through regular visits and assessments.

    • Tocilizumab
    • Upadacitinib
  • Study of sarilumab in the treatment of juvenile idiopathic arthritis in children and adolescents

    This is a trial that aims to find the right dose of a drug called sarilumab for treating children and teenagers aged 1 to 17 years old with Systemic Juvenile Idiopathic Arthritis. Sarilumab is given as an injection under the skin. The main goal is to understand how the body processes this drug in young patients, so they can receive an adequate dose for treating their condition.

    The study will last for about 166 weeks, which is a little over 3 years. It starts with a 4-week screening period, followed by a 12-week treatment phase where the patients will receive repeated doses of sarilumab. After that, there is a 144-week extension phase where the patients can continue receiving the drug, and finally a 6-week follow-up period.

    During the first 12 weeks, the researchers will closely monitor the levels of sarilumab in the patients’ blood to understand how their bodies handle the drug. They will look at the maximum concentration reached, the total amount of drug exposure over time, and the levels just before each new dose. This information will help them determine the right dose and dosing schedule for children and adolescents with Systemic Juvenile Idiopathic Arthritis.

    In addition to studying the drug levels, the researchers will also evaluate the effectiveness of sarilumab in reducing the symptoms of this condition and monitor any potential side effects to ensure the drug is safe for long-term use in this age group.

    • Sarilumab
  • Study of ustekinumab and guselkumab in young patients with juvenile psoriatic arthritis

    This here clinical trial is aimin’ to study two different medicines, ustekinumab and guselkumab, for treatin’ a condition called juvenile psoriatic arthritis. This is a type of arthritis that affects young’uns and causes joint pain, swellin’, and stiffness.

    The study will have two groups, one group takin’ ustekinumab and the other takin’ guselkumab. These medicines work by targetin’ certain proteins in the body that cause inflammation, which is the root cause of the arthritis symptoms.

    The main goal of the study is to see how well these medicines work in reducin’ the symptoms of juvenile psoriatic arthritis, like joint pain and swellin’. The study will also look at how the body handles these medicines and if they cause any side effects.

    The study will last for about a year and a half, with regular check-ups and assessments to monitor the participants’ progress.

    • Ustekinumab
    • Guselkumab
  • Study of Adalimumab and Risankizumab in the treatment of juvenile psoriatic arthritis in children

    This clinical trial is evaluating the safety and effectiveness of Risankizumab in the treatment of juvenile arthritis with psoriasis in children. It is a type of arthritis in which the immune system attacks healthy cells and tissues, causing pain, stiffness and swelling in the joints.

    About 40 young participants with juvenile psoriatic arthritis will be randomized to receive Risankizumab or the already approved treatment Adalimumab. Participants will receive medications in the form of subcutaneous injections for 24 weeks. Those who find the treatment effective will continue for another 100 weeks.

    During the study, participants will regularly visit a hospital or clinic where they will undergo medical tests, blood tests, check for side effects and complete questionnaires. This allows us to assess the effectiveness and safety of risankizumab in the treatment of juvenile psoriatic arthritis in children.

    • Risankizumab
    • Adalimumab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • A study assessing the effectiveness of Apremilast in the treatment of juvenile psoriatic arthritis in children and adolescents

    This study examines a drug called apremilast and its effectiveness in treating children aged 5 to 18 years with juvenile arthritis with psoriasis. Psoriatic arthritis can cause pain in the skin and joints. The effectiveness of the drug will be measured using 6 different methods. One group of participants will receive the study drug, and the other group will receive a placebo.

    Researchers will check the child’s well-being, ease of movement, joint pain, presence of joint stiffness, and blood test results indicating inflammation. Children will also mark the degree of pain they feel on a line, with one end indicating no pain and the other end indicating the worst possible pain. Physical fitness and daily activities such as dressing, eating and walking will also be assessed.

    • Placebo
    • Apremilast
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Germany: